Press Resease

CRISPR Genome Editing Market by Applications (Genome Editing, Genetic Engineering, Gene Library, Human Stem Cells, and Other) and by End User (Biotechnology Companies, Pharmaceutical Companies, and Other): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 31-Aug-2018 Category: Biotechnology Report Format : PDF Pages: 110 Report Code: ZMR-3307 Status : Published

Global CRISPR Genome Editing Market expected to generate revenue of around USD 4,271.0 million by end of 2024, growing at a CAGR of around 36.8% between 2018 and 2024. CRISPR refers to clustered regularly interspaced short palindromic repeats, is a genome-editing tool. CRISPR is repetitive palindromic sequences of base pairs

Description

The report covers forecast and analysis for the CRISPR genome editing market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the CRISPR genome editing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the CRISPR genome editing market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the CRISPR genome editing market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the application and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global CRISPR Genome Editing Market

The report provides company market share analysis in order to give a broader overview of the key players in the CRISPR genome editing market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the CRISPR genome editing market on the global and regional basis. 

The study provides a decisive view on the CRISPR genome editing market by segmenting the market based on applications, end users, and regions. The segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The application segment has been segmented into genome editing, genetic engineering, gene library, human stem cells, and other applications. Other segment includes applications in genetically modified crops and organisms, cell line engineering. Genome editing segment holds the maximum share of the application segment. Based on the end user, CRISPR genome editing market has been segmented into biotechnology companies, pharmaceutical companies and other. Other end users included in the report are academic research centers, research institutes etc.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for CRISPR genome editing tools based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as Editas Medicine, CRISPR Therapeutics AG, Horizon Discovery PLC., Sigma-Aldrich, Genscript, Sangamo Biosciences, Inc., Lonza Group AG, Integrated DNA Technologies, New England Biolabs Inc, Origene Technologies Inc., Transposagen Biopharmaceuticals, Thermo Fisher Scientific, Caribou Biosciences, Inc., Precision Biosciences, Cellectis, Intellia Therapeutics, Inc., Novartis among others.

This report segments the global CRISPR Genome Editing Market as follows:

Global CRISPR Genome Editing Market: By Applications

  • Genome Editing
  • Genetic Engineering
  • Gene Library
  • Human Stem Cells
  • Other Applications (Genetically modified crops and organisms, Cell line engineering)

Global CRISPR Genome Editing Market: By End User

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Other End Users (Academic research centers, Research institutes)

Global CRISPR Genome Editing Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global CRISPR Genome Editing Market, 2017 - 2024 (USD Million)
    • 2.2. Global CRISPR Genome Editing Market : Snapshot
  •  
  • Chapter 3. CRISPR Genome Editing - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global CRISPR Genome Editing Market drivers: Impact analysis
      • 3.2.2. Increase in drug discovery initiatives
      • 3.2.3. Rise in birth disorders owing late pregnancies
    • 3.3. Market Restraints
      • 3.3.1. Ethical concerns related to misuse of genome editing
      • 3.3.2. Availability of other gene editing tools
    • 3.4. Opportunities
      • 3.4.1. Developing contract research organizations (CRO) market 3in emerging countries
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by application segment
      • 3.6.2. Market attractiveness analysis, by end user segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global CRISPR Genome Editing Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global CRISPR Genome Editing Market: Company Market Share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global CRISPR Genome Editing Market - Application Segment Analysis
    • 5.1. Global CRISPR Genome Editing Market: Application overview
      • 5.1.1. Global CRISPR Genome Editing Market revenue share, by Application, 2017 and 2024
    • 5.2. Genome Editing
      • 5.2.1. Global CRISPR Genome Editing Market for Genome Editing, 2017 - 2024 (USD Million)
    • 5.3. Genetic Engineering
      • 5.3.1. Global CRISPR Genome Editing Market for Genetic Engineering, 2017 - 2024 (USD Million)
    • 5.4. Gene Library
      • 5.4.1. Global CRISPR Genome Editing Market for Gene Library, 2017 - 2024 (USD Million)
    • 5.5. Human Stem Cells
      • 5.5.1. Global CRISPR Genome Editing Market for Human Stem Cells, 2017 - 2024 (USD Million)
    • 5.6. Other Applications
      • 5.6.1. Global CRISPR Genome Editing Market for Other Applications, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global CRISPR Genome Editing Market - End-User Segment Analysis
    • 6.1. Global CRISPR Genome Editing Market: End User overview
      • 6.1.1. Global CRISPR Genome Editing Market revenue share, by End User, 2017 and 2024
    • 6.2. Biotechnology Companies
      • 6.2.1. Global CRISPR Genome Editing Market for Biotechnology Companies, 2017 - 2024 (USD Million)
    • 6.3. Pharmaceutical Companies
      • 6.3.1. Global CRISPR Genome Editing Market for Pharmaceutical Companies, 2017 - 2024 (USD Million)
    • 6.4. Other End Users
      • 6.4.1. Global CRISPR Genome Editing Market for Other End Users, 2017 - 2024 (USD Million)
  •  
  • Chapter 7. Global CRISPR Genome Editing Market - Regional Segment Analysis
    • 7.1. Global CRISPR Genome Editing Market: Regional overview
      • 7.1.1. Global CRISPR Genome Editing Market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
      • 7.2.2. North America CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.2.3.2. U.S. CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.4. Canada
        • 7.2.4.1. Canada CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.2.4.2. Canada CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.2.5.2. Rest of North America CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
      • 7.3.2. Europe CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.3. Germany
        • 7.3.3.1. Germany CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.3.2. Germany CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.4.2. U.K. CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.5.2. France CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.6. Italy
        • 7.3.6.1. Italy CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.6.2. Italy CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.7. Spain
        • 7.3.7.1. Spain CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.7.2. Spain CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.8. Russia
        • 7.3.8.1. Russia CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.8.2. Russia CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.3.9.2. Rest of Europe CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
      • 7.4.2. Asia Pacific CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.3. China
        • 7.4.3.1. China CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.4.3.2. China CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.4.4.2. Japan CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.5. India
        • 7.4.5.1. India CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.4.5.2. India CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.6. Australia
        • 7.4.6.1. Australia CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.4.6.2. Australia CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
      • 7.5.2. Latin America CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.5.3.2. Brazil CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.4. Mexico
        • 7.5.4.1. Mexico CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.5.4.2. Mexico CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.5. Argentina
        • 7.5.5.1. Argentina CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.5.5.2. Argentina CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.5.6. Rest of Latin America
        • 7.5.6.1. Rest of Latin America CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.5.6.2. Rest of Latin America CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
      • 7.6.2. Middle East and Africa CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.3. Saudi Arabia
        • 7.6.3.1. Saudi Arabia CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.6.3.2. Saudi Arabia CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.4. UAE
        • 7.6.4.1. UAE CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.6.4.2. UAE CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.5. South Africa
        • 7.6.5.1. South Africa CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.6.5.2. South Africa CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.6. Qatar
        • 7.6.6.1. Qatar CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.6.6.2. Qatar CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
      • 7.6.7. Rest of Middle East and Africa
        • 7.6.7.1. Rest of Middle East and Africa CRISPR Genome Editing Market revenue, by Application, 2017 - 2024 (USD Million)
        • 7.6.7.2. Rest of Middle East and Africa CRISPR Genome Editing Market revenue, by End User, 2017 - 2024 (USD Million)
  •  
  • Chapter 8. Company Profile
    • 8.1. Editas Medicine
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. CRISPR Therapeutics AG
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Horizon Discovery PLC.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Integrated DNA Technologies
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. New England Biolabs Inc.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Caribou Biosciences, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Intellia Therapeutics, Inc.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Novartis
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Thermo Fisher Scientific
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Transposagen Biopharmaceuticals
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
    • 8.11. Origene Technologies Inc.
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Therapy portfolio
      • 8.11.4. Business strategy
      • 8.11.5. Recent developments
    • 8.12. Lonza Group AG
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Therapy portfolio
      • 8.12.4. Business strategy
      • 8.12.5. Recent developments

Methodology

Free Analysis

Genome editing techniques refer to addition, deletion, or alteration of genomic DNA sequence at particular locations. CRISPR/Cas9 is a short form for clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9. CRISPR sequences are palindromic in nature which means that the nucleotide sequence is the same in both the directions. Originally, CRISPR is a bacterial defense system in which the bacteria retain snippets of DNA from viruses. These CRISPR arrays help identify and destroy closely related virus DNA from future attacks. Bacteria use Cas9 enzyme to cut foreign DNA from viruses and thus disables the viral infection.

Similar mechanism from bacterial defense system is used in the laboratory. RNA with short guide sequence is synthesized in the laboratory. This RNA is also capable of binding to the Cas9 enzyme. The guide sequence on RNA helps to identify and bind a specific sequence in the genomic DNA. Thus RNA binds to a targeted sequence in the genomic DNA which is then cut by the Cas9 enzyme at the targeted region. Cell’s own DNA repair machinery is used to edit the genome. The sequence of DNA is added, deleted or replaced with a sequence of interest. Currently, the CRISPR genomic editing tool is in its infancy and is used in cell and animal models. 

Global CRISPR Genome Editing Market

Ethical concerns are raised in editing human genomic sequence. In human, genomic editing is limited to the somatic cell level. Editing of germline cells will lead to changes in gene sequences at the embryo level, which could be passed on to future generations. Genome editing at the germline level is illegal in many countries owing to ethical safety and concern. However, genome editing has huge potential in the management of various disorders such as hemophilia, cystic fibrosis, heart disease, sickle cell disease, cancer, human immunodeficiency virus (HIV) infection and mental illness. Owing to potential benefits of CRISPR gene editing technique in complex disorders, it has gained global interest in commercialization of CRISPR gene editing products and leading market players have received large investments and venture capitals for its development and commercialization.

Transcription activator-like effector nuclease (TALENS), meganucleases and zinc finger nucleases (ZFN) are traditional gene-editing technologies. However, design complexity, restrictions in multiple mutations and transfection inefficiencies are few of the drawbacks of these traditional gene-editing techniques. CRISPR technique, on the other hand, is comparatively more accurate, faster and efficient gene editing tool. Although the ethical concerns limit the use of CRISPR genome editing in human, further research and technological advancements would make its use possible in the diagnosis and treatment of complex disorders. 

Novel drug discovery initiatives by pharmaceutical and biotech companies drive the market growth. Other factors contributing to the market growth are late pregnancies causing birth disorders, rising demand for synthetic genes, huge investments in research and development, technological advancements in the field of molecular biology. Nevertheless, ethical issues pertaining to misuse of genome editing is a major concern and may hamper the market growth. Inadequate awareness and availability of other gene editing tools can restrict the growth of global CRISPR genome editing market. Developing contract research organizations (CRO) market in developing nations like India act as an opportunity for CRISPR genome editing market.

The global CRISPR genome editing market has been segmented based on applications, end-user, and region. Various applications of CRISPR genome editing market are genome editing, genetic engineering, gene library, human stem cells, and others. Other segment includes applications in genetically modified crops and organisms, cell line engineering. Genome editing segment holds the maximum share of the application segment. End users for CRISPR Genome Editing market are biotechnology companies, pharmaceutical companies and other. Other end users included in the report are academic research centers, research institutes etc. 
 
North America region will lead the market during the forecast period. Advanced technology and healthcare infrastructure, government fund, and continuous research and development will promote the growth of the market in this region. Second largest market during the forecast period will be Europe, whereas Asia Pacific region will grow at the fastest rate. Favorable government fund for research and development, increased investments in healthcare research by biotech and pharmaceutical companies are some of the factors propelling the growth of the CRISPR genome editing market in this region. Latin America market is anticipated to grow moderately during the forecast period. Noticeable growth is expected for the Middle East and Africa region in the years to come.

Some of the key players in CRISPR genome editing market include Editas Medicine, Horizon Discovery PLC., CRISPR Therapeutics AG, Genscript, Sangamo Biosciences, Inc., Caribou Biosciences, Inc., Lonza Group AG, Transposagen Biopharmaceuticals, Integrated DNA Technologies, New England Biolabs Inc, Origene Technologies Inc., Thermo Fisher Scientific, Sigma-Aldrich Precision Biosciences, Cellectis, Intellia Therapeutics, Inc., Novartis among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com